UPC Analytics
DEEN
Übersicht · Eingereicht: —

UPC_APP_3514/2024

System for ambulatory drug infusion comprising a filling apparatus for flexible containers

SonstigeVorab-EinredeParis CDPreliminary objection—
ÜbersichtEntscheidungenZitateDokumenteZeitverlauf
Parteien

Kläger

  • Tandem Diabetes Care, Inc.
  • Tandem Diabetes Care Europe B.V.
Vertreter: Christof Augenstein (Kather Augenstein Rechtsanwälte PartGmbB); Katharina Brandt (Kather Augenstein Rechtsanwälte PartGmbB); Robert Knaps (Kather Augenstein Rechtsanwälte PartGmbB)

Beklagte

Vertreter: Charlotte Garnitsch (Taylor Wessing N.V.); Wim Maas (Taylor Wessing N.V.); Alexander Rubusch (Taylor Wessing N.V.)
Richter

Französische Kammer — Einzelrichter anonymisiert.

  • Panel member (anonymized)Presiding judge and judge-rapporteur
  • Panel member (anonymized)Legally qualified judge
  • Panel member (anonymized)Technically qualified judge
Patente
  • EP2196231
CPC-Codes: A61M2209/045, A61M5/148, A61M5/14244

Sektor: Pharmaceutical & Medical

Ausgang
Abgewiesen
Eingereicht: —
Erste Entscheidung: 10. Mai 2024
Sprache: —

The Paris Central Division dismissed a preliminary objection by Tandem Diabetes Care contesting the UPC's jurisdiction based on an alleged violation of a standstill agreement before filing the revocation action by Roche Diabetes Care, ruling that breach of a standstill agreement does not constitute grounds for challenging the court's jurisdiction.